Effect of Mastiha supplementation on NAFLD: The MAST4HEALTH randomised, controlled trial
Creators
- Charalampia Amerikanou1
- Stavroula Kanoni2
- Andriana C. Kaliora1
- Angela Barone3
- Mladen Bjelan4
- Giuseppe D'Auria5
- Aristea Gioxari1
- María José Gosalbes6
- Sofia Mouchti3
- Maria G. Stathopoulou7
- Beatriz Soriano8
- Stefan Stojanoski9
- Rajarshi Banerjee3
- Maria Halabalaki10
- Eleni V. Mikropoulou10
- Aimo Kannt11
- John Lamont12
- Carlos Llorens8
- Fernando Marascio13
- Miriam Marascio13
- Francisco J. Roig14
- Ilias Smyrnioudis15
- Iraklis Varlamis16
- Sophie Visvikis-Siest7
- Milan Vukic17
- Natasa Milic4
- Milica Medic-Stojanoska18
- Lucia Cesarini19
- Jonica Campolo20
- Amalia Gastaldelli21
- Panos Deloukas22
- Maria Giovanna Trivella23
- M. Pilar Francino6
- George V. Dedoussis1
- 1. Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, Athens, Greece
- 2. William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.
- 3. Perspectum Ltd, Oxford, UK
- 4. University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
- 5. Sequencing and Bioinformatics Service, Fundació per al Foment de la Investigació Sanitària i Biomèdica de la Comunitat Valenciana (FISABIO-Salut Pública), Avda. Catalunya 21, València 46020, Spain and CIBER en Epidemiología y Salud Pública, Av. Monforte de Lemos 3-5, Madrid 28029, Spain.
- 6. CIBER en Epidemiología y Salud Pública, Av. Monforte de Lemos 3-5, Madrid 28029, Spain and Joint Research Unit in Genomics and Health, Fundació per al Foment de la Investigació Sanitària i Biomèdica de la Comunitat Valenciana (FISABIO) and Institut de Biologia Integrativa de Sistemes (Universitat de València / Consejo Superior de Investigaciones Científicas), Avda. Catalunya 21, València 46020, Spain.
- 7. UMR INSERM U1122; IGE-PCV, University of Loraine, Nancy, France
- 8. Biotechvana, Parc Científic, Universitat de València, Paterna, Valencia, Spain
- 9. University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia and Centre for Imaging Diagnostics, Oncology Insitute of Vojvodina, Sremska Kamenica, Serbia
- 10. Division of Pharmacognosy and Natural Products Chemistry, Department of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece
- 11. Sanofi Research and Development, Industriepark Hoechst, D-65926 Frankfurt, Germany and Institute of Experimental and Clinical Pharmacology and Toxicology, Medical Faculty Mannheim, University of Heidelberg, D-68169 Mannheim, Germany and Fraunhofer Institute for Molecular Biology and Applied Ecology, Division of Translational Medicine and Pharmacology, D-65926 Frankfurt, Germany
- 12. Randox Laboratories Limited, Crumlin, Co. Antrim, Northern Ireland, UK
- 13. Marascio Fernando, Intervideo, 88100 Catanzaro CZ, Italy
- 14. Biotechvana, Parc Científic, Universitat de València, Paterna, Valencia, Spain and Facultad de Ciencias de la Salud, Universidad San Jorge, 50830, Zaragoza, Spain
- 15. Chios Mastic Gum Growers Association, Chios, Greece
- 16. Department of Informatics and Telematics, Harokopio University, Athens, Greece
- 17. Department of Food Technology, Faculty of Technology Zvornik, University of East Sarajevo, 75400 Zvornik, Bosnia and Herzegovina.
- 18. University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia and Clinic for Endocrinology,Diabetes and Metabolic Diseases, Clinical Centre of Vojvodina, Novi Sad, Serbia
- 19. Division of Hepatology and Gastroenterology, Niguarda Ca' Grande Hospital Milan, Italy
- 20. Institute of Clinical Physiology, CNR, Milan, Italy
- 21. Cardiometabolic Risk Unit, Institute of Clinical Physiology, CNR, Pisa, Italy
- 22. William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK and Centre for Genomic Health, Life Sciences, Queen Mary University of London, London, United Kingdom
- 23. Institute of Clinical Physiology, CNR, Milan, Italy and Cardiometabolic Risk Unit, Institute of Clinical Physiology, CNR, Pisa, Italy
Description
NAFLD is an emerging public health issue globally and its prevalence is consistently increasing. Since there is no approved therapy for this liver disease and given that pharmacological treatment will be approved only for NASH, we wanted to investigate if Mastiha could be a non-pharmacological modulator of NAFLD markers.
Mastiha, has been shown to possess antioxidant/anti- inflammatory and lipid lowering properties and could have beneficial effects on hepatic and systemic parameters in subjects with NAFLD. To this aim we designed, MAST4HEALTH, a Marie Sklodowska-Curie Actions (MSCA) Research and Innovation Staff Exchange (RISE) program under the EU Horizon 2020 framework. MAST4HEALTH is a multicenter randomized double blind placebo controlled clinical trial to test Mastiha’s effectiveness as new non-pharmacologic strategy for NAFLD treatment (NCT03135873).
After 6-months of Mastiha supplementation, we observed a significant improvement on microbiota dysbiosis and lipid metabolite levels in patients with NAFLD. Among severely obese patients, Mastiha also reduced markers of liver fibrosis (as assessed via MRI).
This is the pre-peer reviewed version which has been published in final form at 10.1002/mnfr.202001178. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
Files
Figure1.tif
Files
(13.9 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:48ddc9a9387911997e641b19f89e64fb
|
9.7 MB | Preview Download |
|
md5:c67a4517b15c404f66b113f98879573f
|
924.3 kB | Preview Download |
|
md5:edb9802039b47383192a5ffe5a0889ae
|
924.3 kB | Preview Download |
|
md5:77bea2b066d1aad69a698d7be95be5e7
|
90.6 kB | Download |
|
md5:da2d9d717048e5aebe553789f6551a30
|
30.0 kB | Download |
|
md5:c0008abad9672759161d45430961d8ed
|
2.2 MB | Download |